UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 10, 2007
MWI VETERINARY SUPPLY, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 000-51468 | | 02-0620757 |
(State or other jurisdiction of | | (Commission File | | (I.R.S. Employer |
Incorporation) | | Number) | | Identification No.) |
651 S. Stratford Drive, Suite 100, Meridian, ID 83642
(Address of principal executive offices) (Zip Code)
(800) 824-3703
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
MWI Veterinary Supply, Inc. (“MWI”) and Pfizer, Inc. (“Pfizer”) have entered into a Livestock Products Agreement effective December 23, 2006, an Equine Products Marketing Agreement effective January 1, 2007 and a Rimadyl/Clavamox Distribution Agreement effective March 15, 2007, each of which was executed and delivered by Pfizer to MWI on April 10, 2007.
Under the Livestock Products Agreement, MWI is entitled to distribute certain Pfizer products to customers in the cattle and swine fields. In return, MWI is entitled to receive certain service incentives and rebates. MWI is required to maintain sufficient inventory levels to meet anticipated customer demand and to store products in accordance with their respective label instructions. The agreement expires on December 31, 2007 and can be terminated by either party with or without cause upon 30 days prior written notice.
Under the Equine Products Marketing Agreement, MWI is entitled to distribute certain Pfizer products to customers in the equine field. In return, MWI is entitled to receive certain service incentives and rebates. MWI is required to maintain sufficient staffing levels of sales representatives and store and handle inventory under appropriate conditions that will maintain the quality and integrity of the products. The agreement expires on December 31, 2007 and can be terminated by either party with or without cause upon 30 days prior written notice.
Under the Rimadyl/Clavamox Distribution Agreement, MWI is entitled to distribute the Rimadyl and Clavamox products offered by Pfizer. In return, MWI is entitled to receive certain service incentives and rebates. MWI is required to maintain sufficient staffing levels of sales representatives and store and handle inventory under appropriate conditions that will maintain the quality and integrity of the products. The agreement expires on December 31, 2008 and can be terminated by Pfizer with or without cause upon 30 days, and either party can terminate the agreement immediately upon written notice for material breach of the contract.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MWI VETERINARY SUPPLY, INC. |
| | |
Date: April 10, 2007 | By: | /s/ James F. Cleary, Jr. |
| | James F. Cleary, Jr. |
| | President and Chief Executive Officer |
